Johnson & Johnson $JNJ Shares Sold by Allianz SE

Allianz SE reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 5.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 133,221 shares of the company’s stock after selling 8,085 shares during the period. Allianz SE’s holdings in Johnson & Johnson were worth $20,350,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in JNJ. Brighton Jones LLC boosted its stake in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Wealth Group Ltd. purchased a new stake in shares of Johnson & Johnson during the first quarter worth $218,000. Smart Money Group LLC raised its position in shares of Johnson & Johnson by 6.5% in the first quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock valued at $1,109,000 after buying an additional 407 shares during the last quarter. Leo Wealth LLC lifted its stake in shares of Johnson & Johnson by 0.3% in the first quarter. Leo Wealth LLC now owns 376,853 shares of the company’s stock worth $62,497,000 after buying an additional 1,156 shares in the last quarter. Finally, United Community Bank boosted its position in Johnson & Johnson by 1.6% during the first quarter. United Community Bank now owns 19,801 shares of the company’s stock worth $3,284,000 after acquiring an additional 309 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of JNJ opened at $194.52 on Thursday. The firm has a 50-day simple moving average of $185.13 and a two-hundred day simple moving average of $169.48. The stock has a market cap of $468.65 billion, a PE ratio of 18.78, a P/E/G ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $195.55. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have commented on the stock. UBS Group increased their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. Raymond James Financial boosted their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Stifel Nicolaus raised their target price on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research note on Wednesday, October 15th. Finally, Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.